1Lipton A. Management of bone metastases in breast cancer [J ]. Curr Treat Options Oncol, 2005, 6 (2) : 161-171.
2Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy[J]. Drugs, 2003, 63(4): 417-437.
3Skerjanec A, BerensonJ, Hsu C, et al. The pharmacokinefics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J]. J Clin Pharmacol, 2003, 43(2): 154-162.
4Croucher P, Jagdev S, Coleman R. The anti-tumor potential of zoledronic acid [J]. Breast, 2003, 12 Suppl 2: S30--S36.
5Saad F, Gleason DM, Murray R, et al. A randomized,placebo---controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2002, 94(19): 1458-1468.
6Reid IR , BrownJP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density[J]. N EnglJ Med, 2002, 346(9): 653-661.
8Marx RE. Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws:a growing epidemic[J]. J Oral MaxiUofac Surg, 2003, 61(9): 1115-1117.
9Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate[J]. BMJ, 2004, 328(7435): 335-336.
二级参考文献9
1Conte P, Coleman R. Bisphosphonates ha the treatment of skeletal metastases[J]. Semin Oncol, 2004, 31(5 Suppl 10): 59～63.
2Cameron D. Proven efficacy of zoledron acid in the treatment of bone metastases in patients with breast cancer and other malignancies[J]. Breast, 2003, 12 Supple 2:S22～S29.
3Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases [J]. Semin Oncol. 2001, 28(2 Suppl 6): 11～16.
4Quint LE, Tummala S, Brisson LJ. et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer[J]. Ann Thorac Surg, 1996, 62(1): 246～250.
6Berenson JR, Rosen LS, Howell A. et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [J]. Cancer, 2001, 91(7): 1191～1200.
7Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the trealanent of hypercalcemia of malignancy: apooled analysis of two randomized, controlled clinical trials [J]. J Clin Oncol,2001, 19(2): 558～567.
8Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolyfic lesions of multiple myeloma: a phase Ⅲ, double-blind, comparative trial[J]. Cancer J, 2001, 7(5): 377～387.
9Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid[J]. N Engl J Med, 2003, 349(17): 1676～1679.
